To include your compound in the COVID-19 Resource Center, submit it here.

PT003: Additional Phase IIb data

Additional data from a double-blind, dose-ranging Phase IIb trial in 118 patients with moderate to very severe COPD showed that PT003 significantly improved FEV AUC from 0-12 hours at day

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE